retatrutide clinical trial results 2025 New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight Retatrutide FDA Approval 2025–2026: Phase

Republican State Representative Vanessa Grossl of Georgetown announced today she has filed a bill to strengthen state oversight of G-L-P 1 compounded drugs

Your provider determines whether GLOW Blend peptide therapy may be appropriate

FAQ Frequently Asked Questions About GHK-Cu What is GHK-Cu used for in research

Helps enhance endurance and physical performance

Medicaid programs in North Carolina, South Carolina, Michigan, New Hampshire, and California have announced plans to eliminate or narrow access to GLP-1 weight-loss treatment in some cases limiting it only to people who are morbidly obese. The reversal reflects tightening budgets, slowing revenue growth, and rising spending demands